Blood test for leftover cancer cells after ovarian cancer treatment
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study is for women with advanced ovarian cancer who have finished first treatment and are in complete remission. It uses a blood test to look for tiny amounts of leftover cancer cells, which could help guide future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 19 years old or older.
- You have been diagnosed with one of these types of ovarian cancer: high-grade serous, endometrioid, clear cell, or mixed type.
- Your cancer was stage III or IV at diagnosis.
- You have finished primary or interval debulking surgery and platinum-based chemotherapy.
- After finishing chemotherapy, your scans and exams show no signs of cancer (complete response).
- You are willing to have blood drawn multiple times for this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a special blood test (called personalized ctDNA MRD) to see if it can give early warning about cancer returning after treatment. If you have cervical cancer that can be treated with surgery or chemoradiation, and you haven't had treatment yet, you may be eligible.
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
This study collects a blood sample before you have surgery or a biopsy for an ovarian mass. Researchers will test whether a new blood test can accurately identify ovarian cancer by looking at DNA patterns in your blood. The results will help doctors understand if this blood test could help detect ovarian cancer earlier in the future.
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
This trial looks at tiny molecules in the blood to help diagnose ovarian germ cell tumors. It compares results from people with malignant (cancerous) tumors, benign (non-cancerous) tumors, and those without any gynecologic condition.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.